The University of Chicago Header Logo

Connection

Olatoyosi Odenike to MAP Kinase Kinase 2

Back to Details
This is a "connection" page, showing publications Olatoyosi Odenike has written about MAP Kinase Kinase 2.
Olatoyosi Odenike
Connection Strength
0.168
MAP Kinase Kinase 2
  1. Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study. Clin Lymphoma Myeloma Leuk. 2019 07; 19(7):431-440.e13.
    View in: PubMed
    Score: 0.168
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.